IP Library Granted Patent US 9,279,107
Granted Patent B2
US 9,279,107 · App. 13/341,059 · Granted Mar 8, 2016

Simplified basic media for human pluripotent cell culture

Inventors: Guokai Chen (Rockville, MD); James A. Thomson (Madison, WI)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
C12N5/0696C12N5/0606C12N2500/02C12N2500/32C12N2500/38C12N2500/90C12N2501/115C12N2501/15C12N2501/33C12N2501/727C12N2501/845C12N2501/998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,279,107
App. No.
13/341,059
Granted
Mar 8, 2016
Kind
B2
Abstract

Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.

Claims (27)

1. A defined, albumin-free medium free of any component obtained from a non-human animal, the medium comprising water, salts, amino acids, vitamins, glucose, a fibroblast growth factor (FGF), selenium, transferrin, one of insulin, insulin-like growth factor 1 (IGF1), and insulin-like growth factor 2 (IGF2), and one of transforming growth factor beta (TGF-β) and NODAL, each in an amount sufficient to support human pluripotent stem cell proliferation.

2. The medium of claim 1 , wherein the IGF1 is Long-IGF1.

3. A method for culturing human pluripotent stem cells, the method comprising the steps of:

placing pluripotent stem cells on a matrix; and

contacting the cells with a defined albumin-free medium free of any component obtained from a non-human animal, the medium comprising water, salts, amino acids, vitamins, glucose, an FGF, selenium, transferrin, one of insulin, IGF1, and IGF2, and one of TGF-β and NODAL, each in an amount sufficient to support pluripotent stem cell proliferation.

4. The method of claim 3 , wherein the IGF1 is Long-IGF1.

5. The method of claim 3 , wherein the matrix comprises laminin.

6. The method of claim 3 , wherein the matrix comprises vitronectin.

7. The method of claim 3 , wherein the cells are contacted with the medium under hypoxic conditions.

8. The method of claim 3 , wherein the human pluripotent stem cells are human embryonic stem cells.

9. The method of claim 3 , wherein the human pluripotent stem cells are human induced pluripotent stem cells.

10. A method for cloning a human pluripotent stem cell, the method comprising the step of:

plating human pluripotent stem cells at cloning density in a defined albumin-free medium that is free of any component obtained from a non-human animal, the medium comprising water, salts, amino acids, vitamins, a glucose, an FGF, selenium, transferrin, one of insulin, IGF1, and IGF2, and one of TGF-β and NODAL, wherein the medium supports human pluripotent stem cell cloning.

11. The method of claim 10 , wherein the IGF1 is Long-IGF1.

12. The method of claim 10 , wherein the medium further comprises a ROCK inhibitor.

13. The method of claim 12 , wherein the ROCK inhibitor is selected from the group consisting of HA100 and Y27632.

14. The method of claim 10 , wherein the medium further comprises blebbistatin.

15. A method of cryopreserving human pluripotent stem cells, the method comprising the step of:

freezing human pluripotent stem cells in a defined albumin-free medium that is free of any component obtained from a non-human animal, the medium comprising water, salts, amino acids, vitamins, glucose, an FGF, selenium, transferrin, one of insulin, IGF1, and IGF2, and one of TGF-β and NODAL.

16. The method of claim 15 , wherein the IGF1 is Long-IGF1.

17. The defined albumin-free medium of claim 1 consisting essentially of the water, salts, amino acids, vitamins, glucose, FGF, selenium, transferrin, one of insulin, IGF1, and IGF2, and one of TGF-β and NODAL.

18. The defined albumin-free medium of claim 1 , wherein the medium comprises TGF-β.

19. The defined albumin-free medium of claim 1 , wherein the medium comprises NODAL.

20. The defined albumin-free medium of claim 1 , further comprising a ROCK inhibitor.

21. The defined albumin-free medium of claim 20 , wherein the ROCK inhibitor is selected from the group consisting of HA100 and Y27632.

22. The defined albumin-free medium of claim 1 , further comprising blebbistatin.

23. The defined albumin-free medium of claim 1 comprising one of IGF1 and IGF2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2015
From: THOMSON, JAMES; CHEN, GUOKAI
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 036479/0045 →
CONFIRMATORY LICENSE Recorded Jan 30, 2012
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027614/0653 →
Continuity (3)
Continuation In Part 13204354 · Aug 5, 2011
Provisional Application 61371128 · Aug 5, 2010
Related Publication 20120178166A1 · Jul 12, 2012